Novartis Cancer Unit Escapes Securities Suit

Law360, New York (July 13, 2012, 1:08 PM ET) -- A California federal judge on Wednesday dismissed a proposed securities class action accusing Novartis AG subsidiary Genoptix Inc.'s executives of feathering their nests with company cash as sales figures tanked, ruling the firm's inaccurate revenue forecasts were forward-looking statements immune to litigation.

Investors spotlighted 80 allegedly deceptive statements by Genoptix’s top brass, but more than half were protected under the Private Securities Litigation Act’s safe-harbor provisions, U.S. District Judge Cathy Ann Bencivengo said.

Shareholders had argued that company leaders failed to make it clear that actual...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Construction Workers Pension Trust Fund v. Genoptix, Inc et al


Case Number

3:10-cv-02502

Court

California Southern

Nature of Suit

Securities/Commodities

Judge

Cathy Ann Bencivengo

Date Filed

December 6, 2010

Law Firms

Companies